Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy, a peptide similar to the natural hormone is combined with radioactive material such as Yttrium and Lutetium, to produce radionuclide which is then injected into the patient’s body. This combination binds to the neuroendocrine tumors in the body. It is a cell targeting type of therapy since it delivers a high dose of radiation directly to the tumor cells.

Market Dynamics

Rising number of cancer cases in Italy is expected to drive the Italy peptide receptor radionuclide therapy (PRRT) market growth during the forecast period. For instance, as per data published by the Epidemiology Unit, Agency for Health Protection of Milan, Corso Italia, in 2012- 2015, 3,803 patient  diagnosed with colorectal cancer. Cancer patients in the age group below 50 years accounted for 22.25%, of the total cancer cases that were reported and patients in the age group of 50 to 64 years accounted for 17.65%, and patients over the age of 65 accounted 20.80%.

Furthermore, according the WHO, in 2018, around 43,837 cases of prostate cancer were reported, which contributed around 10% of the total cancer cases recorded in Italy.

However, side effects associated with peptide receptor radionuclide therapy may negatively impact growth of the peptide receptor radionuclide therapy market. The side effects occur on the body part which is treated with radiation. Some of the common side effects faced by patients undergoing radiation therapy are nausea, vomiting, abdominal discomfort or pain, and in some cases, temporary hair loss and sub-acute hematology toxicity. Hence, this may hamper the Italy peptide receptor radionuclide therapy market growth.

Key features of the study:

• This report provides in-depth analysis of the Italy peptide receptor radionuclide therapy (PRRT) market, market size (USD Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2026-2033, considering 2025 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles the key player in the Italy peptide receptor radionuclide therapy (PRRT) market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• The key player covered as a part of this study is Novartis International AG
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The Italy peptide receptor radionuclide therapy (PRRT) market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers for Italy Peptide Receptor Radionuclide Therapy (PRRT) Market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

• Drug Type Insights (Revenue, USD Mn, 2026 - 2033)
  • Lutetium (Lu-177)-based      
  • Yttrium (Y-90)-based
• Indication Insights (Revenue, USD Mn, 2026 - 2033)
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Foregut Neuroendocrine Tumor
  • Midgut Neuroendocrine Tumor
  • Hindgut Neuroendocrine Tumor
• Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
• Key Players Insights
  • Novartis International AG
  • Curium Pharma
  • ITM Isotope Technologies Munich SE
  • Eckert & Ziegler AG